Ⅲb+Ⅳ期晚期肺癌治疗效果分析  

Curative Effect of the treatment in the advanced of non-small cell lung cancer

作　　者：汪济东[1] 姜庆玲[1] 孙琦[1] 张扬[1] 张建中[1] 

机构地区：[1]中国人民解放军海军安庆医院肿瘤内科,安徽安庆246003

出　　处：《临床肺科杂志》2013年第4期705-706,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的分析53例符合入组标准的晚期非小细胞肺癌患者的临床资料,统计其中位生存期和生存率。方法Ⅲb+Ⅳ期NSCLC中位生存期和生存率统计分析。结果生存率:男性:1年内27例死亡(27/45 60%);1年生存率40%(18/45);2年生存率15.6%(7/45);3年生存率6.7%(3/45 4.4%);4年年生存率2.2%(1/45)。女性:1年内5例死亡(5/8 62.5%);1年生存率37.5%3/8);2年0(0/80);中位生存期统计:男性15.47月,女9.25月。讨论晚期NSCLC在以化疗为主的综合治疗后有较好的中位生存期和年生存率,可以维持较好的生活质量。Objective Were reviewed and summarized of 53 in the advanced of non-small cell lung cancer, Comparing regimens WHO solid tumor efficacy of different treatment, recorded The median surival time and survival rate. Methods The median surival time and survival rate in the advanced of non-small cell lung cancer. Results 1. Mail Group ：The 1-year, 2-year,3-year,4-year survival rates were 40% （18/45） ,15.6% （7/45） ,6.7% （3/45 4.4% ） ,2. 2% （1/45） ; Fmail Group ： The 1-year, 2-year survival rates were 37. 5% 3/8） ,0 （0/8 0 ）o 2. The median surival time： mail 15.47 month, femail 9. 25 month o Conclusion The therapy of stage Ⅲ b/Ⅳ NSCLC should based on the principles Evidence-Based Medicine and provide effective individual chemotherapy approaches and cycles, and the improvement of KPS before chemotherapy is significant for better prognostic.

关 键 词：非小细胞肺癌 生存率 中位生存期 

分 类 号：R734.2[医药卫生—肿瘤]